BHWM
VKTX icon

Beaird Harris Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Beaird Harris Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108 Hold
3
– – ﹤0.01% 681
2026
Q1 		$90 Hold
3
– – ﹤0.01% 661
2025
Q4 		$97 Hold
3
– – ﹤0.01% 680
2025
Q3 		$73 Buy
+3
New +$89 ﹤0.01% 711

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Beaird Harris Wealth Management's VKTX Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 3 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Beaird Harris Wealth Management first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Beaird Harris Wealth Management held 3 shares of Viking Therapeutics worth $108 as of Q2 2026.
  • Beaird Harris Wealth Management left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #681 holding.
  • Beaird Harris Wealth Management first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.